


EG00229

### Chemical Properties

|                   |  |
|-------------------|--|
| CAS No.:          | 1210945-69-9   |
| Formula:          | C19H20F3N7O7S3   |
| Molecular Weight: | 611.6  |
| Appearance:       | N/A  |
| Storage:          | 0-4°C for short term (days to weeks), or -20°C for long term (months). |



### Biological Description

|               |   |
|---------------|---|
| Description   | EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 $\mu$ M, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2. EG00229 is a neuropilin 1 (NRP1) receptor antagonist.   |
| Targets(IC50) | 125I-VEGF-A binding to PAE/NRP1: 8 $\mu$ M<br>bt-VEGF-A binding to purified NRP1 b1 domain: 3 $\mu$ M   |
| In vitro      | EG00229 selectively inhibits radiolabeled 125I-VEGF-A binding to porcine aortic endothelial (PAE)/NRP1, but not VEGFR2-expressing cells, with an IC50 of 8 $\mu$ M. EG00229 also inhibits VEGF-A binding to lung carcinoma A549 and prostate carcinoma DU145 cells, which express NRP1, but not VEGFR1 and VEGFR2, with similar potency. Binding of VEGF-A to human umbilical vein endothelial cells (HUVECs), which express VEGFR2, VEGFR1, and NRP1, is also inhibited by EG00229 with an IC50 of 23 $\mu$ M. EG00229 (0-100 $\mu$ M; 48 hours; A549 cells) treatment causes a significant reduction in cell viability over a 48 hours incubation. EG00229 demonstrates inhibition of VEGF-A binding to NRP1 and attenuates VEGFR2 phosphorylation in endothelial cells. Inhibition of migration of endothelial cells is also observed in HUVECs. |
| In vivo       | EG00229 treatment substantially reduces tumor growth and visible vascularization.   |

### Solubility Information

|            |   |
|------------|---|
| Solubility | DMSO: 41.4 mg/mL (67.69 mM)<br>( < 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|---|

#### Preparing Stock Solutions

|       | 1mg      | 5mg      | 10mg      |
|-------|----------|----------|-----------|
| 1 mM  | 1.635 mL | 8.175 mL | 16.351 mL |
| 5 mM  | 0.327 mL | 1.635 mL | 3.27 mL   |
| 10 mM | 0.164 mL | 0.818 mL | 1.635 mL  |
| 50 mM | 0.033 mL | 0.164 mL | 0.327 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Jarvis A, et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 2010 Mar 11;53(5):2215-26.
2. Grun D, et al. VEGF-A acts via neuropilin-1 to enhance epidermal cancer stem cell survival and formation of aggressive and highly vascularized tumors. Oncogene. 2016 Aug 18;35(33):4379-87.

**Inhibitors · Natural Compounds · Compound Libraries**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481